Follow
Or-Yam Revach, PhD
Or-Yam Revach, PhD
Postdoctoral fellow at MGH Cancer Center and Harvard Medical School
Verified email at mgh.harvard.edu
Title
Cited by
Cited by
Year
ERBB2 drives YAP activation and EMT-like processes during cardiac regeneration
A Aharonov, A Shakked, KB Umansky, A Savidor, A Genzelinakh, D Kain, ...
Nature cell biology 22 (11), 1346-1356, 2020
1482020
Mechanical interplay between invadopodia and the nucleus in cultured cancer cells
OY Revach, A Weiner, K Rechav, I Sabanay, A Livne, B Geiger
Scientific reports 5 (1), 9466, 2015
842015
The interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasion
OY Revach, B Geiger
Cell adhesion & migration 8 (3), 215-225, 2014
702014
Biomechanical regulation of focal adhesion and invadopodia formation
OY Revach, I Grosheva, B Geiger
Journal of cell science 133 (20), jcs244848, 2020
682020
20S proteasomes secreted by the malaria parasite promote its growth
E Dekel, D Yaffe, I Rosenhek-Goldian, G Ben-Nissan, Y Ofir-Birin, ...
Nature communications 12 (1), 1172, 2021
562021
Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells
OY Revach, O Sandler, Y Samuels, B Geiger
Cancer Research 79 (10), 2634-2648, 2019
422019
Targeting TBK1 to overcome resistance to cancer immunotherapy
Y Sun, O Revach, S Anderson, EA Kessler, CH Wolfe, A Jenney, CE Mills, ...
Nature 615 (7950), 158-167, 2023
382023
Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients
TJ LaSalle, ALK Gonye, SS Freeman, P Kaplonek, I Gushterova, KR Kays, ...
Cell Reports Medicine 3 (10), 2022
382022
The involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cells
OY Revach, SE Winograd-Katz, Y Samuels, B Geiger
Experimental cell research 343 (1), 82-88, 2016
342016
Immunomodulatory Properties of Leishmania Extracellular Vesicles During Host-Parasite Interaction: Differential Activation of TLRs and NF-κB Translocation by …
PM Nogueira, A de Menezes-Neto, VM Borges, A Descoteaux, ...
Frontiers in Cellular and Infection Microbiology 10, 380, 2020
332020
Targeting TANK-binding kinase 1 (TBK1) in cancer
OY Revach, S Liu, RW Jenkins
Expert opinion on therapeutic targets 24 (11), 1065-1078, 2020
312020
Malaria parasites both repress host CXCL10 and use it as a cue for growth acceleration
Y Ofir-Birin, H Ben Ami Pilo, A Cruz Camacho, A Rudik, A Rivkin, ...
Nature communications 12 (1), 4851, 2021
242021
Sialylated N‐glycans mediate monocyte uptake of extracellular vesicles secreted from Plasmodium falciparum‐infected red blood cells
H Ben Ami Pilo, S Khan Khilji, J Lühle, K Biskup, B Levy Gal, ...
Journal of Extracellular Biology 1 (2), e33, 2022
82022
Proliferation and EMT trigger heart repair
A González-Iglesias, MA Nieto
Nature Cell Biology 22 (11), 1291-1292, 2020
32020
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy
OY Revach, AM Cicerchia, O Shorer, B Petrova, S Anderson, J Park, ...
bioRxiv, 2024.02. 12.579184, 2024
2024
In vivo gain-of-function screen identifies CREB5, a novel ECM modulator that promotes immunotherapy resistance via the Collagen-Lair1 axis
P Tiwari, K Colvin, S Kim, A Kammula, S Anderson, OY Revach, M Vyas, ...
CANCER IMMUNOLOGY RESEARCH 11 (12), 2023
2023
Abstract B021: In vivo gain-of-function screen identifies CREB5, a novel ECM modulator that promotes immunotherapy resistance via the Collagen-Lair1 axis
P Tiwari, K Colvin, S Kim, A Kammula, S Anderson, OY Revach, M Vyas, ...
Cancer Immunology Research 11 (12_Supplement), B021-B021, 2023
2023
628 Circulatory plasma proteomic biomarkers combined with high-throughput proteomic screen of patient-derived organotypic tumor spheroids predict responses to immunotherapy in …
M Rucevic, A Mehta, RW Jenkins, A Kar, A Cicerchia, OY Revach, Y Sun, ...
Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023
2023
561 Targeting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy
OY Revach, A Cicerchia, M Sade-Feldman, S Anderson, B Petrova, ...
Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023
2023
Targeting CD38 on exhausted T cells overcomes resistance to cancer immunotherapy
OY Revach, AM Cicerchia, M Sade-Feldman, S Anderson, RT Manguso, ...
Cancer Research 83 (7_Supplement), 3250-3250, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20